Spyre Therapeutics CEO Cameron Turtle sells common shares worth $1.32 million

Spyre Therapeutics CEO Cameron Turtle sold 15,000 common shares on July 1, valued at approximately $1.32 million. The transaction occurred at prices ranging from $87.44 to $88.91 per share. Following this sale, Turtle's holdings decreased to 582,540 common shares.

Spyre Therapeutics CEO and director Turtle Cameron sold 15,000 common shares on July 1. * Sales priced at $87.44, $88.12, $88.91 per share. * Holdings fell to 582,540 common shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636282-26-000086), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here